[1] |
ALMERIA S, DUBEY J P. Foodborne transmission of Toxoplasma gondii infection in the last decade. An overview[J]. Res Vet Sci, 2021, 135:371-385.
|
[2] |
高俊莹, 张东超, 李璇, 等. 弓形虫表面抗原SAG1黏附宿主细胞表面硫化肝素的特性研究[J]. 畜牧兽医学报, 2019, 50(9):1874-1881.GAO J Y, ZHANG D C, LI X, et al. The characteristic study of Toxoplasma gondii surface antigen SAG1 adhering to heparan sulfate on the host cell surface[J]. Acta Veterinaria et Zootechnica Sinica, 2019, 50(9):1874-1881. (in Chinese)
|
[3] |
MILNE G, WEBSTER J P, WALKER M. Toxoplasma gondii:an underestimated threat?[J]. Trends Parasitol, 2020, 36(12):959-969.
|
[4] |
ELSHEIKHA H M, MARRA C M, ZHU X Q. Epidemiology, pathophysiology, diagnosis, and management of cerebral toxoplasmosis[J]. Clin Microbiol Rev, 2020, 34(1):e00115-19.
|
[5] |
ALDAY P H, DOGGETT J S. Drugs in development for toxoplasmosis:advances, challenges, and current status[J]. Drug Des Devel Ther, 2017, 2017:273-293.
|
[6] |
FENG X C, CAO S J, QIU F, et al. Traditional application and modern pharmacological research of Artemisia annua L[J]. Pharmacol Ther, 2020, 216:107650.
|
[7] |
CHOI W H, LEE I A. The mechanism of action of ursolic acid as a potential anti-Toxoplasmosis agent, and its immunomodulatory effects[J]. Pathogens, 2019, 8(2):61.
|
[8] |
OLIVEIRA C B S, MEURER Y S R, MEDEIROS T L, et al. Anti-Toxoplasma activity of estragole and thymol in murine models of congenital and noncongenital toxoplasmosis[J]. J Parasitol, 2016, 102(3):369-376.
|
[9] |
GOZALBES R, GÁLVEZ J, GARCíA-DOMENECH R, et al. Molecular search of new active drugs against Toxoplasma gondii[J]. SAR QSAR Environ Res, 1999, 10(1):47-60.
|
[10] |
ZHANG H B, LIU Q, CAO Y J, et al. Microbial production of sabinene-a new terpene-based precursor of advanced biofuel[J]. Microb Cell Fact, 2014, 13:20.
|
[11] |
SI H F, XU C Y, ZHANG J L, et al. Licochalcone A:an effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo[J]. Int J Parasitol:Drugs Drug Resist, 2018, 8(2):238-245.
|
[12] |
QIAN W F, WANG H, SHAN D, et al. Activity of several kinds of drugs against Neospora caninum[J]. Parasitol Int, 2015, 64(6):597-602.
|
[13] |
ZHANG J L, SI H F, LI B, et al. Myrislignan exhibits activities against Toxoplasma gondii RH strain by triggering mitochondrial dysfunction[J]. Front Microbiol, 2019, 10:2152.
|
[14] |
JANETKA J W, HOPPER A T, YANG Z P, et al. Optimizing pyrazolopyrimidine inhibitors of calcium dependent protein kinase 1 for treatment of acute and chronic toxoplasmosis[J]. J Med Chem, 2020, 63(11):6144-6163.
|
[15] |
MURAKOSHI F, BANDO H, SUGI T, et al. Nullscript inhibits Cryptosporidium and Toxoplasma growth[J]. Int J Parasitol:Drugs Drug Resist, 2020, 14:159-166.
|
[16] |
HAN Y M, ADEYEMI O S, KABIR M H B, et al. Screening of compound libraries for inhibitors of Toxoplasma growth and invasion[J]. Parasitol Res, 2020, 119(5):1675-1681.
|
[17] |
LU Y N, ZHAO X D, XU X, et al. Arctigenin exhibits hepatoprotective activity in Toxoplasma gondii-infected host through HMGB1/TLR4/NF-κB pathway[J]. Int Immunopharmacol, 2020, 84:106539.
|
[18] |
LI J X, GUO H P, GALON E M, et al. Hydroxylamine and carboxymethoxylamine can inhibit Toxoplasma gondii growth through an aspartate aminotransferase-independent pathway[J]. Antimicrob Agents Chemother, 2020, 64(3):e01889-19.
|
[19] |
GUO H P, GAO Y, JIA H L, et al. Characterization of strain-specific phenotypes associated with knockout of dense granule protein 9 in Toxoplasma gondii[J]. Mol Biochem Parasitol, 2019, 229:53-61.
|
[20] |
SMITH N C, GOULART C, HAYWARD J A, et al. Control of human toxoplasmosis[J]. Int J Parasitol, 2021, 51(2-3)95-121.
|
[21] |
RADKE J B, BURROWS J N, GOLDBERG D E, et al. Evaluation of current and emerging antimalarial medicines for inhibition of Toxoplasma gondii growth in vitro[J]. ACS Infect Dis, 2018, 4(8):1264-1274.
|
[22] |
ROSENBERG A, LUTH M R, WINZELER E A, et al. Evolution of resistance in vitro reveals mechanisms of artemisinin activity in Toxoplasma gondii[J]. Proc Natl Acad Sci U S A, 2019, 116(52):26881-26891.
|
[23] |
WANG D W, XING M G, El-ASHRAM S, et al. Determination of lumefantrine as an effective drug against Toxoplasma gondii infection-in vitro and in vivo study[J]. Parasitology, 2021, 148(1):122-128.
|
[24] |
YAMAMOTO M, ICHINOHE T, WATANABE A, et al. The antimalarial compound Atovaquone inhibits zika and dengue virus infection by blocking E protein-mediated membrane fusion[J]. Viruses, 2020, 12(12):1475.
|
[25] |
KHALID A, TAKAGI H, PANTHEE S, et al. Development of a terpenoid-production platform in Streptomyces reveromyceticus SN-593[J]. ACS Synth Biol, 2017, 6(12):2339-2349.
|
[26] |
CAO Y J, ZHANG H B, LIU H, et al. Biosynthesis and production of sabinene:current state and perspectives[J]. Appl Microbiol Biotechnol, 2018, 102(4):1535-1544.
|
[27] |
RYU Y, LEE D, JUNG S H, et al. Sabinene prevents skeletal muscle atrophy by inhibiting the MAPK-MuRF-1 pathway in rats[J]. Int J Mol Sci, 2019, 20(19):4955.
|
[28] |
PARK B I, KIM B S, KIM K J, et al. Sabinene suppresses growth, biofilm formation, and adhesion of Streptococcus mutans by inhibiting cariogenic virulence factors[J]. J Oral Microbiol, 2019, 11(1):1632101.
|
[29] |
ZHOU S X, WEI C X, ZHANG C, et al. Chemical composition, phytotoxic, antimicrobial and insecticidal activity of the essential oils of Dracocephalum integrifolium[J]. Toxins, (Basel), 2019, 11(10):598.
|
[30] |
VIMAL A, PAL D, TRIPATHI T, et al. Eucalyptol, sabinene and cinnamaldehyde:potent inhibitors of salmonella target protein L-asparaginase[J]. 3 Biotech, 2017, 7(4):258.
|
[31] |
GUO J, COKER A R, WOOD S P, et al. Structure and function of the thermostable L-asparaginase from Thermococcus kodakarensis[J]. Acta Crystallogr D Struct Biol, 2017, 73(Pt 11):889-895.
|
[32] |
CACHUMBA J J M, ANTUNES F A F, PERES G F D, et al. Current applications and different approaches for microbial L-asparaginase production[J]. Braz J Microbiol, 2016, 47(Suppl 1):77-85.
|
[33] |
ZHANG Y, LAI B S, JUHAS M. Deactivation and mislocalization of Toxoplasma gondii rhoptry protein 18 induced by a single amino acid mutation on the proton transport catalytic aspartic acid[J]. Microbiol Res, 2020, 230:126352.
|